Quest Diagnostics Inc (NYSE:DGX) Stake Lowered by Seizert Capital Partners LLC

Seizert Capital Partners LLC cut its stake in shares of Quest Diagnostics Inc (NYSE:DGX) by 19.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,115 shares of the medical research company’s stock after selling 39,548 shares during the quarter. Seizert Capital Partners LLC owned approximately 0.13% of Quest Diagnostics worth $17,218,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. CENTRAL TRUST Co grew its holdings in shares of Quest Diagnostics by 11.2% during the second quarter. CENTRAL TRUST Co now owns 2,834 shares of the medical research company’s stock valued at $293,000 after purchasing an additional 285 shares during the last quarter. Aperio Group LLC grew its holdings in Quest Diagnostics by 11.8% in the 2nd quarter. Aperio Group LLC now owns 120,853 shares of the medical research company’s stock worth $12,304,000 after buying an additional 12,752 shares in the last quarter. Atwater Malick LLC grew its holdings in Quest Diagnostics by 2.8% in the 2nd quarter. Atwater Malick LLC now owns 33,074 shares of the medical research company’s stock worth $3,367,000 after buying an additional 894 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in Quest Diagnostics by 24.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 629,689 shares of the medical research company’s stock worth $56,622,000 after buying an additional 125,051 shares in the last quarter. Finally, AE Wealth Management LLC bought a new position in Quest Diagnostics in the 2nd quarter worth approximately $377,000. 90.89% of the stock is owned by institutional investors.

In other news, Chairman Stephen H. Rusckowski sold 244,565 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $100.00, for a total transaction of $24,456,500.00. Following the completion of the sale, the chairman now owns 457,614 shares in the company, valued at approximately $45,761,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Guinan sold 73,005 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $100.00, for a total value of $7,300,500.00. Following the sale, the insider now owns 139,022 shares of the company’s stock, valued at approximately $13,902,200. The disclosure for this sale can be found here. Company insiders own 1.86% of the company’s stock.

A number of equities analysts recently issued reports on the company. Canaccord Genuity increased their price objective on Quest Diagnostics from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Credit Suisse Group increased their price objective on Quest Diagnostics from $99.00 to $105.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. JPMorgan Chase & Co. increased their price objective on Quest Diagnostics from $100.00 to $111.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Goldman Sachs Group lowered Quest Diagnostics from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $90.00 to $85.00 in a report on Monday, July 15th. Finally, Zacks Investment Research raised Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 price objective for the company in a report on Wednesday, July 24th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $105.06.

NYSE DGX traded down $1.02 on Friday, reaching $101.60. 1,607,037 shares of the stock traded hands, compared to its average volume of 871,475. The firm’s fifty day simple moving average is $101.32 and its 200 day simple moving average is $95.18. The company has a quick ratio of 0.77, a current ratio of 0.82 and a debt-to-equity ratio of 0.58. The company has a market cap of $13.89 billion, a price-to-earnings ratio of 16.10, a P/E/G ratio of 2.09 and a beta of 0.88. Quest Diagnostics Inc has a 12 month low of $78.95 and a 12 month high of $111.54.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.69 by $0.04. The firm had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a return on equity of 15.05% and a net margin of 9.64%. The firm’s quarterly revenue was up 1.8% on a year-over-year basis. During the same period last year, the company posted $1.75 EPS. As a group, equities research analysts forecast that Quest Diagnostics Inc will post 6.5 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.09%. The ex-dividend date of this dividend is Thursday, October 3rd. Quest Diagnostics’s payout ratio is currently 33.60%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Article: How a Put Option Works

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.